• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine

Drug Database Powered by:

  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Microbiome Times

Finance

PepsiCo to Acquire fast-growing prebiotic soda brand for $1.95 billion

March 21, 2025 Microbiome Times

PepsiCo, Inc. (NASDAQ: PEP) (“PepsiCo”) announced on Monday that it has entered into a definitive agreement to acquire poppi, a fast-growing prebiotic soda brand, for $1.95 billion, including $300 million of anticipated cash tax benefits for a […]

Pharma & Human Health

Bloom Science Demonstrates Durable Weight Loss in Overweight Individuals in Phase 1 Trial of BL-001 

March 7, 2025 Microbiome Times

Bloom Science, Inc., a clinical-stage biotech company focused on the development of novel therapies for metabolic and neurological disorders, today announced that BL-001, an investigational oral therapy designed to replicate the positive effects of the ketogenic […]

Editor's Choice

Dynamic Microbiome Abundance Profiling: A new tool to solve challenges in microbiome analysis

March 5, 2025 Microbiome Times

With bacterial strains of the same species exhibiting remarkably different characteristics, it is vital biotic developers accurately characterise what strains are present in their product. This enables developers to maximise the biotics’ therapeutic potential, provide […]

Pharma & Human Health

Synthetic microbiome therapy suppresses bacterial infection without antibiotics

March 5, 2025 Microbiome Times

A synthetic microbiome therapy, tested in mice, protects against severe symptoms of a gut infection that is notoriously difficult-to-treat and potentially life threatening in humans, according to a team of researchers at Penn State. The […]

Finance

BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million

February 26, 2025 Microbiome Times

BiomX Inc. (NYSE American: PHGE, the “Company” or “BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it has entered into a securities purchase agreement […]

Editor's Choice

Scientists decode diet from stool DNA – no questions asked

February 24, 2025 Microbiome Times

Scientists have developed a breakthrough method to track diet using stool metagenomic data. Developed by researchers at the Institute for Systems Biology (ISB), the new method, called MEDI (Metagenomic Estimation of Dietary Intake), detects food-derived […]

Editor's Choice

Hervé Affagard talks Phase 3 results, the regulatory landscape and industry collaborations

February 20, 2025 Microbiome Times

In early January MaaT Pharma made waves in the pharma world with the announcement of positive topline results for their phase 3 trial of MaaT013 in acute Graft-versus-Host Disease. With robust efficacy and safety data, […]

Pharma & Human Health

Global “sisterhood” seeks to understand what makes a healthy vaginal microbiome

February 12, 2025 Microbiome Times

Vaginas host a complex microcosm of bacteria and yeasts that can fluctuate over time. However, little is known about these microbial communities and their roles in a person’s health, and 9 out of 10 studies […]

Pharma & Human Health

Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

January 27, 2025 Microbiome Times

Vedanta Biosciences today announced the publication of additional results from the Phase 2 CONSORTIUM study for its lead candidate, VE303, which is being evaluated for prevention of recurrent Clostridioides difficile infection (rCDI). The new analyses were published […]

Pharma & Human Health

Changes in microbiome predict risk for sexually transmitted disease

January 22, 2025 Microbiome Times

Women who develop bacterial vaginosis (BV) often later acquire chlamydia, a common and potentially serious sexually transmitted bacterial infection. Now, researchers at Albert Einstein College of Medicine, Roswell Park Comprehensive Cancer Center, and the Icahn School of Medicine at Mount […]

Finance

Owlstone Medical Announces $27 Million USD First Close in Series E Financing Round

January 15, 2025 Microbiome Times

Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced a first closing of $27 million (circa £22 million) in its Series E financing round. The […]

Posts navigation

« 1 … 3 4 5 … 77 »

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • MRM Health Raises €55 Million Series B to Advance Microbiome-Based Biotherapeutic Product Pipeline
    September 4, 2025
  • Targeting the ileo-colonic region: Innovative solutions for sensitive APIs
    August 21, 2025
  • EXPERT’Biome CDMO by Lallemand at Microbiome Times Forum
    June 23, 2025
  • DynaMAP – Precision Metagenomics beyond Sequencing
    May 27, 2025
  • The Selection of a Pre-Clinical Model is Driven by the Specific Research Question
    May 13, 2025
sign up

Sign up to the Microbiome Times newsletter